SARomics Biostructures Company Blog
On our blog, we share company updates, highlight new publications featuring our team’s contributions, discuss advancements in our methods, and explain the fundamental concepts and principles that underpin our work. Our goal is to promote our research practices and enhance our clients’ understanding of our work.
The following list displays the various blog categories.
-
synchrotron X-ray Crystallography in drug Discovery
We highlight a study conducted by the AstraZeneca team on synchrotron X-ray crystallography in drug discovery (Käck & Sjögren, 2024).
-
Crystallographic Fragment Screening In Drug Discovery: Background & Advantages
Technical developments have made crystallographic fragment screening the most effective method for screening fragment libraries. Here, we provide a brief overview of the method and its requirements.
-
The Exciting World of Macrocyclic Peptide Drug Structures
Macrocyclic peptide drug structures (often 4 to 24 amino acids) fall between small-molecule drugs and biologics (such as monoclonal antibodies). We discuss the unique features of these structures.
-
Early Drug Discovery Services: Why Do You Need A CRO?
We discuss the the early drug discovery services market and highlight the integrated drug discovery CRO services provided by SARomics Biostructures.
-
How was our 2024?
It was a year marked by the most significant changes in recent memory: a new home for the company, four new team members, new collaborations, new publications, a revamped homepage, and a greatly expanded list of off-the-shelf structures.
-
DNA-Encoded Library Screening For Drug Discovery
SARomics Biostructures AB and Vipergen ApS partner to offer hit and lead identification services based on Vipergen’s unique DNA-encoded library (DEL) screening technology.
-
NMR spectroscopic Higher-Order Structure Analysis of Biosimilars
In the this article we discuss evidence that shows that NMR spectroscopy is far superior to other established methods for biosimilar’s higher order structure analysis.
-
WAC™ Fragment screening technology: Principles & Advantages
In this article, we discuss weak affinity chromatography (WAC™), the proprietary fragment screening technique jointly owned by SARomics Biostructures and Red Glead Discovery.
-
2023 – New Publications & Collaborations
In this article, we will discuss some significant publications and company activities in 2023. The publications showcase our expertise in the three main areas of our services: X-ray crystallography, NMR spectroscopy, and integrated drug discovery.
-
Protein-Ligand Interactions: Room Temperature or Cryo-Crystallography?
After many years of cryo-crystallography dominance, room-temperature X-ray crystallography using synchrotron radiation has returned. We discuss the application of room-temperature X-ray crystallography in drug design.
-
Therapeutic Antibodies & Biosimilars: Comparative Analysis
In this post, we discuss therapeutic antibodies and biosimilars and the need for biosimilar comparability analysis and characterization, with a focus on methods for assessing structural comparability.
-
TAK1 inhibitor secures € 950 million
Using an integrated drug discovery approach, first-in-class TAK1 kinase inhibitors were designed in a hit-to-lead program run in close cooperation between three partners, SARomics Biostructures, Red Glead Discovery, and Aqilion.
